August 13, 2026 11:50 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Netaji row: Suvendu Adhikari govt strips BJP MP Anant Maharaj of state honour | Sukhbir Badal attacked by Nihang Sikh with kirpan at Maharashtra gurdwara; assailant detained | ‘If you cannot do it, we will pass an order’: Supreme Court’s final warning to Centre on food labels | ‘Time to move on’: Bombay HC sends strong message in Vijay Mallya-bank dispute | Netaji row explodes in Bengal: Suvendu Adhikari orders police action over ‘derogatory’ posts | Kolkata's NRS Hospital nurse found dead in washroom during night shift | RG Kar rape-murder case takes fresh turn as ex-TMC MLA Nirmal Ghosh arrested over cremation probe | ‘Govt has nothing to hide’: Amit Shah says ‘ready for debate’ on NEET crackdown; Rahul Gandhi hits back, ‘not interested in lecture’ | Tata Sons leadership shock: N Chandrasekaran won’t seek reappointment as chairman after February 2027 | ISI-linked Pakistani national arrested in Bengal over 'espionage' targeting Army, BSF, Railways
Corona Remedies
Corona Remedies listed at 38% premium. Photo: ChatGPT

Corona Remedies storms Dalal Street! Shares list at 38% premium on debut

| @indiablooms | Dec 15, 2025, at 11:19 am

Mumbai/IBNS: Pharmaceutical firm Corona Remedies made a strong debut on the stock market on Monday, listing at a 38% premium over its IPO price on the National Stock Exchange (NSE), media reports said.

The company’s shares were listed at ₹1,470 apiece on the NSE, marking a 38.42% premium over the issue price.

On the BSE, the stock debuted at ₹1,452 per share, a 36.72% premium.

The ₹655.37-crore IPO, which was entirely an offer for sale, had a price band of ₹1,008–1,062 per share and was open for subscription from December 8 to 10.

Headquartered in Ahmedabad, Gujarat, Corona Remedies is an Indian pharmaceutical company with a strong presence in branded generics, catering to both chronic and acute therapy segments.

The robust listing underscored strong investor confidence in the company’s growth outlook and financial performance, reflecting sustained demand for quality pharma IPOs in the Indian market.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.